Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates oral yeast immunotherapy prevents Clostridioides difficile infection in mice, indicating high potential for clinical translation.
to constitutively secrete a single tetra-specific antibody that potently and broadly neutralized both toxins and demonstrated protection against primary and recurrent CDI in both prophylactic and therapeutic mouse models of disease. This yeast immunotherapy is orally administered, can be used concurrently with antibiotics, and may have potential as a prophylactic against CDI risk and as a therapeutic for patients with CDI.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: